“Innovation is the Name of the Game: Novel Modalities for Oncology” featured Raphi Levy, CFO of Alpha Tau Medical, Mohit Rawat, President & CBO of Fusion Pharmaceuticals, Julie Eastland, President & CEO of Harpoon Therapeutics, and Eric Poma, CEO of Molecular Templates. The panel was moderated by Jennifer Kim.
• Alpha Tau Medical walked through its Alpha DaRT technology, an implanted alpha-emitter therapy for cancer radiation therapy that has demonstrated proof of concept in multiple models, including in patients with cutaneous or head and neck squamous cell carcinoma.
• Fusion is focused on harnessing alpha particles emitted from medical isotopes to kill cancer cells.
• Harpoon is developing a novel class of T cell engagers through its three proprietary platforms: TriTAC, ProTriTAC, and TriTAC-XR. Currently, resources and efforts are focused on lead TriTAC programs, HPN328 and HPN217, and ProTriTAC candidate, HPN601.
• Molecular Templates is building a scaffold of novel therapeutics focused on ETBs and currently has three drugs in the clinic.
#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare